donafenib + PD-1 inhibitor + TACE

This combination therapy regimen is being evaluated as a first-line treatment for patients with unresectable advanced hepatocellular carcinoma (HCC). It consists of donafenib, a programmed cell death protein 1 (PD-1) inhibitor, and transarterial chemoembolization (TACE). Donafenib, developed by Suzhou Zelgen Biopharmaceuticals, is a novel oral small molecule multikinase inhibitor and a deuterated derivative of sorafenib that targets multiple receptor tyrosine kinases, including VEGFR, PDGFR, and various Raf kinases. The PD-1 inhibitor component acts as a checkpoint inhibitor to enhance the immune system's anti-tumor response. TACE is a localized procedure that delivers chemotherapy directly to the liver tumor while simultaneously blocking its blood supply. This triple combination approach aims to improve overall survival and potentially convert unresectable tumors into resectable ones through transformation therapy.

Brand names

Zuniduo

Other names

Donafenib + PD-1 + TACE